Poop pills for painful skin? fecal transplant trial targets hidradenitis
NCT ID NCT07668713
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This pilot study tests whether fecal microbiota transplantation (FMT) can improve moderate to severe hidradenitis suppurativa (HS), a painful skin condition. Researchers will give 24 adults a single FMT and track changes in their skin lesions over 12 weeks. The goal is to see if altering gut bacteria can reduce inflammation and flare-ups.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
fecal microbiota transplantation (FMT)
What this could lead to
If it works, this could point toward a new treatment option for hidradenitis suppurativa by restoring healthy gut bacteria.
What could go wrong
This is a very early phase 1 pilot with only 24 participants, so results may not apply broadly. FMT carries risks of infection or digestive upset, and the effect on HS is unproven.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FECAL MICROBIOTA TRANSPLANTATION (FMT) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
CH Rodez
Rodez, France
Contact
-
CHU Bordeaux, Hôpital Saint-André
Bordeaux, France
Contact
-
CHU Clermont Ferrand
Clermont-Ferrand, France
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
CHU Clermont Ferrand, PIC/CIC
Clermont-Ferrand, France
Contact
-
CHU Lyon
Lyon, France
Contact
-
CHU Marseille, La Timone
Marseille, France
Contact
-
CHU Montpellier
Montpellier, France
Contact